Small bowel injury in low-dose aspirin users

详细信息    查看全文

• 作者：Hiroki Endo (1)
  Eiji Sakai (1)
  Takayuki Kato (1)
  Shotaro Umezawa (1)
  Takuma Higurashi (1)
  Hidenori Ohkubo (1)
  Atsushi Nakajima (1)
  
  1. Department of Gastroenterology and Hepatology ; Yokohama City University School of Medicine ; 3-9 Fukuura ; Kanazawa-ku ; Yokohama ; 236-0004 ; Japan
  
• 关键词：Low ; dose aspirin ; Capsule endoscopy ; Small bowel injury ; Enteric ; coated aspirin
• 刊名：Journal of Gastroenterology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：50
• 期：4
• 页码：378-386
• 全文大小：426 KB
• 参考文献：1. Awtry, EH, Loscalzo, J (2000) Aspirin. Circulation 101: pp. 1206-1218 CrossRef
  Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324: pp. 71-86 CrossRef
  2. Patrono, C, Garc铆a Rodr铆guez, LA, Landolfi, R, Baigent, C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: pp. 2373-2383 CrossRef
  3. Weil, J, Colin-Jones, D, Langman, M, Lawson, D, Logan, R, Murphy, M (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: pp. 827-830 CrossRef
  4. Patrono, C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: pp. 1287-1294 CrossRef
  5. Iddan, G, Meron, G, Glukhovsky, A, Swain, P (2000) Wireless capsule endoscopy. Nature 405: pp. 417 CrossRef
  6. Yamamoto, H, Sekine, Y, Sato, Y, Higashiwaza, T, Miyata, T, Iino, S (2001) Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc 53: pp. 216-220 CrossRef
  7. Graham, DY, Opekun, AR, Willingham, FF, Qureshi, WA (2005) Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3: pp. 55-59 CrossRef
  8. Maiden, L, Thjodleifsson, B, Theodors, A, Gonzalez, J, Bjarnason, I (2005) A quantitative analysis of NSAID-induced small bowel pathology by capsule endoscopy. Gastroenterology 128: pp. 1172-1178 CrossRef
  9. Maiden, L, Thjodleifsson, B, Seigal, A, Bjarnason, II, Scott, D, Birgisson, S (2007) Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 5: pp. 1040-1045 CrossRef
  10. Goldstein, JL, Eisen, GM, Lewis, B, Gralnek, IM, Zlotnick, S, Fort, JG (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: pp. 133-141 CrossRef
  11. Goldstein, JL, Eisen, GM, Lewis, B, Gralnek, IM, Aisenberg, J, Bhadra, P (2007) Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 25: pp. 1211-1222 CrossRef
  12. Endo, H, Hosono, K, Inamori, M, Kato, S, Nozaki, Y, Yoneda, K (2009) Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 79: pp. 44-51 CrossRef
  13. Endo, H, Hosono, K, Inamori, M, Nozaki, Y, Yoneda, K, Fujita, K (2009) Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 44: pp. 544-549 CrossRef
  14. Leung, WK, Bjarnason, I, Wong, VW, Sung, JJ, Chan, FK (2007) Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 369: pp. 614 CrossRef
  15. Manetas, M, O鈥橪oughlin, C, Kelemen, K, Barkin, JS (2004) Multiple small-bowel diaphragms: a cause of obscure GI bleeding diagnosed by capsule endoscopy. Gastrointest Endosc 60: pp. 848-851 CrossRef
  16. Matsumoto, T, Kudo, T, Esaki, M, Yano, T, Yamamoto, H, Sakamoto, C (2008) Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 43: pp. 490-496 CrossRef
  17. Stattery, J, Warlow, CP, Shorrock, CJ, Langman, MJ (1995) Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin鈥攁nalysis of gastrointestinal bleeding during the UK-TIA trial. Gut 37: pp. 509-511 CrossRef
  18. Higuchi, K, Umegaki, E, Watanabe, T, Yoda, Y, Morita, E, Murano, M (2009) Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 44: pp. 879-888 CrossRef
  19. Davies, NM, Saleh, JY, Skjodt, NM (2000) Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci. 3: pp. 137-155
  20. Reuter, BK, Davies, NM, Wallace, JL (1997) Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: pp. 109-117 CrossRef
  21. Bjarnason, I, Hayllar, J, MacPherson, AJ, Russell, AS (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small intestine in humans. Gastroenterology 104: pp. 1832-1847
  22. Somasundaram, S, Sigthorsson, G, Simpson, RJ, Watts, J, Jacob, M, Tavares, IA (2000) Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 14: pp. 639-650 CrossRef
  23. Sigthorsson, G, Simpson, RJ, Walley, M, Anthony, A, Foster, R, Hotz-Behoftsitz, C (2002) COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122: pp. 1913-1923 CrossRef
  24. Ligumsky, M, Golanska, EM, Hansen, DG, Kauffman, GL (1983) Aspirin can inhibit gastric mucosa cyclo-oxygenase without causing lesions in rat. Gastroenterology 84: pp. 756-761
  25. Somasundaram, S, Rafi, S, Hayllar, J, Sigthorsson, G, Jacob, M, Price, AB (1997) Mitochondrial damage: a possible mechanism of the 鈥渢opical鈥?phase of NSAID induced injury to the rat intestine. Gut 41: pp. 344-353 CrossRef
  26. Bjarnason, I, Williams, P, Smethurst, P, Peters, TJ, Levi, AJ (1986) Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27: pp. 1292-1297 CrossRef
  27. Sigthorsson, G, Tibble, J, Hayllar, J, Menzies, I, Macpherson, A, Moots, R (1998) Intestinal permeability and inflammation in patients on NSAIDs. Gut 43: pp. 506-511 CrossRef
  28. Catanoso, M, Lo Gullo, R, Giofr茅, MR, Pallio, S, Tortora, A, Lo Presti, M (2001) Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol 30: pp. 77-81 CrossRef
  29. Jenkins, RT, Rooney, PJ, Jones, DB, Bienenstock, J, Goodacre, RL (1987) Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy?. Br J Rheumatol 26: pp. 103-107 CrossRef
  30. Twiss, IM, Burggraaf, J, Schoemaker, RC, Elburg, RM, Hartigh, J, Cohen, AF (2001) The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 69: pp. 431-437 CrossRef
  31. Smecuol, E, Pinto Sanchez, MI, Suarez, A, Argonz, JE, Sugai, E (2009) Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 7: pp. 524-529 CrossRef
  32. Shiotani, A, Haruma, K, Nishi, R, Fujita, M, Kamada, T, Honda, K (2010) Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 45: pp. 292-298 CrossRef
  33. Mizukami, K, Murakami, K, Abe, T, Inoue, K, Uchida, M, Okimoto, T (2011) Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 17: pp. 5117-5122 CrossRef
  34. Mehdizadeh, S, Lo, SK (2006) Treatment of small-bowel diaphragm disease by using double-balloon enteroscopy. Gastrointest Endosc 64: pp. 1014-1017 CrossRef
  35. Watanabe, T, Sugimori, S, Kameda, N, Machida, H, Okazaki, H, Tanigawa, T (2008) Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 6: pp. 1279-1282 CrossRef
  36. Shiotani, A, Honda, K, Murao, T, Ishii, M, Fujita, M, Matsumoto, H (2011) Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury. Scand J Gastroenterol 46: pp. 281-286 CrossRef
  37. Watari, I, Oka, S, Tanaka, S, Aoyama, T, Imagawa, H, Shishido, T (2013) Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol 13: pp. 108 CrossRef
  38. Watari, I, Oka, S, Tanaka, S, Igawa, A, Nakano, M, Aoyama, T (2014) Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion 89: pp. 225-231 CrossRef
  39. Endo, H, Hosono, K, Higurashi, T, Sakai, E, Iida, H, Sakamoto, Y (2011) Quantitative analysis of low-dose aspirin-associated small bowel injury using a capsule endoscopy scoring index. Dig Endosc 23: pp. 56-61 CrossRef
  40. Endo, H, Higurashi, T, Hosono, K, Sakai, E, Sekino, Y, Iida, H (2011) Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 46: pp. 894-905 CrossRef
  41. Cryer, B, Feldman, M (1999) Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117: pp. 17-25 CrossRef
  42. Gralnek, IM, Defranchis, R, Seidman, E, Leighton, JA, Legnani, P, Lewis, BS (2008) Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 27: pp. 146-154 CrossRef
  43. Ehrhard, F, Nazeyrollas, P, Brixi, H, Heurgue-Berlot, A, Thi茅fin, G (2013) Proximal predominance of small bowel injury associated with uncoated low-dose aspirin therapy: a video capsule study in chronic users. Eur J Gastroenterol Hepatol 25: pp. 1265-1272 CrossRef
  44. Fujimori, S, Gudis, K, Takahashi, Y, Seo, T, Yamada, Y, Ehara, A (2010) Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 40: pp. 504-510 CrossRef
  45. Watanabe, T, Higuchi, K, Kubota, A, Nishio, H, Tanigawa, T, Shiba, M (2008) Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: pp. 181-187 CrossRef
  46. Konaka, A, Kato, S, Tanaka, A, Kunikata, T, Korolkiewicz, R, Takeuchi, K (1999) Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 40: pp. 517-524 CrossRef
  47. Banoob, DW, McCloskey, WW, Webster, W (2002) Risk of gastric injury with enteric- versus nonenteric-coated aspirin. Ann Pharmacother 36: pp. 163-166 CrossRef
  48. Dammann, HG, Burkhardt, F, Wolf, N (1999) Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 13: pp. 1109-1114 CrossRef
  49. Blondon, H, Barbier, JP, Mah茅, I, Deverly, A, Kolsky, H, Bergmann, JF (2000) Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formation versus regular formation in healthy volunteers. Fundam Clin Pharmacol 14: pp. 155-157 CrossRef
  50. Lanza, FL, Royer, GL, Nelson, RS (1980) Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303: pp. 136-138 CrossRef
  51. Petroski, D (1993) Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 15: pp. 314-320
  52. Endo, H, Sakai, E, Higurashi, T, Yamada, E, Ohkubo, H, Iida, H (2012) Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 44: pp. 833-838 CrossRef
  53. Hirata, Y, Kataoka, H, Shimura, T, Mizushima, T, Mizoshita, T, Tanida, S (2011) Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 46: pp. 803-809 CrossRef
  54. Lanas, A, Scheiman, J (2007) Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 23: pp. 163-173 CrossRef
  55. Endo H, Sakai E, Taniguchi L, Kessoku T, Komiya Y, Ezuka A, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014. doi: 10.1016/j.gie.2014.03.024 .
  56. Watanabe, T, Tanigawa, T, Nadatani, Y, Nagami, Y, Sugimori, S, Okazaki, H (2013) Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis 45: pp. 390-395 CrossRef
  57. Arora, G, Singh, G, Triadafilopoulos, G (2009) Proton pump inhibitor for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 7: pp. 725-735 CrossRef
  58. Konaka, A, Kato, S, Tanaka, A, Kunikata, T, Korolkiewicz, R, Takeuchi, K (1999) Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 40: pp. 517-524 CrossRef
  59. Watanabe, T, Nishio, H, Tanigawa, T, Yamagami, H, Okazaki, H, Watanabe, K (2009) Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 297: pp. G506-G513 CrossRef
  60. Watanabe, T, Higuchi, K, Kobata, A, Nishio, H, Tanigawa, T, Shiba, M (2008) Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: pp. 181-187 CrossRef
  61. Lombardo, L, Foti, M, Ruggia, O, Chiecchio, A (2010) Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 8: pp. 504-508 CrossRef
  62. Compare, D, Pica, L, Rocco, A, Giorgi, F, Cuomo, R, Sarnelli, G (2011) Effects of long-tern PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 41: pp. 380-386 CrossRef
  63. Jacobs, C, Coss Adame, E, Attaluri, A, Valestin, J, Rao, SS (2013) Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 37: pp. 1103-1111 CrossRef
  64. Wallace, JL, Syer, S, Denou, E, Palma, G, Vong, L, McKnight, W (2011) Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dyspiosis. Gastroenterology 114: pp. 1314-1322 CrossRef
  65. Yoda, Y, Amagase, K, Kato, S, Tokioka, S, Murano, M, Kakimoto, K (2010) Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 61: pp. 287-294
  66. Higuchi, K, Yoda, Y, Amagase, K, Kato, S, Tokioka, S, Murano, M (2009) Prevention of NSAID-induced small bowel intestinal mucosal injury: prophylactic potential of lansoprazole. J Clin Biochem Nutr 45: pp. 125-130 CrossRef
  67. Fuller, R (1991) Probiotics in human medicine. Gut 32: pp. 439-442 CrossRef
  68. Rembacken, BJ, Snelling, AM, Hawkey, PM, Chalmers, DM, Axon, AT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: pp. 635-639 CrossRef
  69. Sood, A, Midha, V, Makharia, GK, Ahuja, V, Singal, D, Goswami, P (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: pp. 1202-1209 CrossRef
  70. Montalto, M, Gallo, A, Curigliano, V, D鈥橭nofrio, F, Santoro, L, Covino, M (2010) Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy鈥攁 randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 32: pp. 209-214 CrossRef
  71. Park, SH, Cho, CS, Lee, OY, Jun, JB, Lin, SR, Zhou, LY (2007) Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial鈥擲TORM STUDY. J Clin Biochem Nutr 40: pp. 148-155 CrossRef
  72. Terano, A, Arakawa, T, Sugiyama, T, Suzuki, H, Joh, T, Yoshikawa, T (2007) Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 42: pp. 690-693 CrossRef
  73. Kim, HK, Kim, JI, Kim, JK, Han, JY, Park, SH, Choi, KY (2007) Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 52: pp. 1776-1782 CrossRef
  74. Kent, TH, Cardelli, RM, Stamler, FW (1969) Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 54: pp. 237-249
  75. Sakurai, K, Sasabe, H, Koga, T, Konishi, T (2004) Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res 38: pp. 487-494 CrossRef
  76. Chitapanarux, T, Praisontarangkul, OA, Lertprasertsuke, N (2008) An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci 53: pp. 2896-2903 CrossRef
  77. Kurokawa, S, Katsuki, S, Fujita, T, Saitoh, Y, Ohta, H, Nishikawa, K (2014) A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol 49: pp. 239-244 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Oncology
  Surgical Oncology
  Hepatology
  Internal Medicine
  Colorectal Surgery
  
• 出版者：Springer Japan
• ISSN：1435-5922

文摘

The use of low-dose aspirin (LDA) is well known to be associated with an increased risk of serious upper gastrointestinal complications, such as peptic ulceration and bleeding. Until recently, attention was mainly focused on aspirin-induced damage of the stomach and duodenum. However, recently, there has been growing interest among gastroenterologists on the adverse effects of aspirin on the small bowel, especially as new endoscopic techniques, such as capsule endoscopy (CE) and balloon-assisted endoscopy, have become available for the evaluation of small bowel lesions. Preliminary CE studies conducted in healthy subjects have shown that short-term administration of LDA can induce mild mucosal inflammation of the small bowel. Furthermore, chronic use of LDA results in a variety of lesions in the small bowel, including multiple petechiae, loss of villi, erosions, and round, irregular, or punched-out ulcers. Some patients develop circumferential ulcers with stricture. In addition, to reduce the incidence of gastrointestinal lesions in LDA users, it is important for clinicians to confirm the differences in the gastrointestinal toxicity between different types of aspirin formulations in clinical use. Some studies suggest that enteric-coated aspirin may be more injurious to the small bowel mucosa than buffered aspirin. The ideal treatment for small bowel injury in patients taking LDA would be withdrawal of aspirin, however, LDA is used as an antiplatelet agent in the majority of patients, and its withdrawal could increase the risk of cardiovascular/cerebrovascular morbidity and mortality. Thus, novel means for the treatment of aspirin-induced enteropathy are urgently needed.